Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics.
about
Treatment of hepatitis C in children: a systematic reviewKASL clinical practice guidelines: management of hepatitis CViral hepatitis B and C in childrenDiagnosis, management, and treatment of hepatitis C: an updateIndian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016.Pegylated IFN-α and ribavirin: emerging data in the treatment of special populations.Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of AmerPharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunologyInfluence of body mass index on outcome of pediatric chronic hepatitis C virus infection.Ophthalmologic complications in children with chronic hepatitis C treated with pegylated interferonHepatitis C in the pediatric population: transmission, natural history, treatment and liver transplantation.Treatment of hepatitis C virus infectionGuidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of theManaging HCV infection in pediatric age group: suggested recommendations.The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C.Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in childrenTreatment and follow up of children with chronic hepatitis C in Albania.Pegylated interferon for chronic hepatitis C in children affects growth and body composition: results from the pediatric study of hepatitis C (PEDS-C) trial.Perinatal hepatitis C virus infection: diagnosis and managementTreatment options for chronic hepatitis B and C infection in children.Regional differences in hepatitis C treatment with peginterferon and ribavirin in Japan: a retrospective cohort studyManagement of chronic hepatitis C: consensus guidelines.Design of the PEDS-C trial: pegylated interferon +/- ribavirin for children with chronic hepatitis C viral infection.IL28B SNP rs12979860 is the Critical Predictor for Sustained Viral Response in Chinese Children Aged 1 to 6 Years with Chronic Hepatitis C.Safety and transparency of pediatric drug trials.Pediatric Dosing and Body Size in Biotherapeutics.Biotherapeutic bioanalysis: a multi-indication case study review.Chronic hepatitis C in children--review of natural history at a National Centre.Treatment of chronic viral hepatitis C in children and adolescents: UK experience.Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations.Systematic review with meta-analysis: comparison between therapeutic regimens for paediatric chronic hepatitis C.Efficacy and safety of pegylated interferon in children and adolescents infected with chronic hepatitis C: a preliminary study.Vertical genotype 1 HCV infection treated successfully in the second year of life: a case report.Association of Hepatitis C Virus Infection and Interleukin-28B Gene Polymorphism in Chinese Children.Interferon-α plus ribavirin yields 98 % sustained virologic response in children aged 1-5 years with iatrogenic chronic hepatitis C.Population pharmacokinetics of peginterferon alfa-2b in pediatric patients with chronic hepatitis C.Is liver biopsy mandatory in children with chronic hepatitis C?Spontaneous clearance of hepatitis C virus in vertically infected children.Long-term outcome of hepatitis C virus infections acquired after pediatric liver transplantation.Current treatment options and response rates in children with chronic hepatitis C.
P2860
Q21136318-4F877437-B657-4C63-B9F4-CE413F251C7BQ26752471-371EB520-674A-4AE2-AC86-723303560664Q27473273-3948A7C9-A078-4859-8C5B-6F4E22C8AAB6Q29619682-7852EAC8-4868-4B3A-BE2A-0DB0133BEDFBQ30355190-D15C3140-D5B3-4E56-A459-55317E781600Q30733177-8C7F524D-A814-49F9-ADD4-36B12BDE7FCDQ33650105-DCE31BD7-8E82-448B-9604-A75680BC870DQ33827819-AC389836-45D8-4FFF-9768-B6A6CB89DE61Q34023077-739D9D65-7891-4F23-B01A-C3618EB9468EQ34023159-F4F8B7CE-3FB7-4E60-946C-E14E3CE7A27BQ34093840-69871751-77F4-4C80-A6D1-3C2DE62C9AA4Q34099424-53A23164-C9DF-4022-BAEF-C2748809DDF2Q34212799-024C3E60-73D5-4771-B692-0AFD2140DEBAQ34411942-F3D3149E-AA60-40D0-A05E-0AE67E6DFBAFQ34588247-B2781BD1-937D-4248-85E2-F17AE7FB0BADQ34861058-69909AEF-03CD-48BA-B7E2-A17B41E630A5Q35735622-2624D88F-05D2-4248-B64A-1ADFBA8348F5Q36055220-28F981D1-58F1-48D5-9B3F-7ACF623786F2Q36153246-3275D536-49FC-49E0-9460-BF18D85C270FQ36607394-7CE56C6D-E1EE-4B0F-9CD1-20F36D355DCEQ36733568-1DFBE823-0192-4A19-BF66-8E1FFA9DE1EEQ36849347-1025574C-3821-4F9A-96D2-B73CD9B241AFQ37126749-C69F7672-4F8D-4ED2-81CB-485E653026A7Q37428173-9D289B24-9285-494B-BC7A-FA5B68CC09D1Q37472770-09B9578B-180F-480B-A62B-CF746577ACB6Q37666711-DB34C0A1-7AF8-44BD-82BB-D7CD41CF634AQ37854629-7737F6BD-6DAD-422D-919E-D4C8E4EF6CC8Q37931376-E0A991A5-EE49-4C20-8043-E9021CC09B0FQ38184887-05C07BF4-9A7C-4B20-ADC6-D3CF461D1897Q38203823-95437393-5C41-4739-A4B7-267F2C9591D2Q38450468-639EBAF6-8381-49C4-B50A-08CBA0D3BB04Q38854176-4AC7DEDF-27E8-4352-91A0-883EB21BF9DFQ40265125-EB51D6D1-FE0E-4C2D-AB90-03F349F3202BQ40407622-BAB3B292-900F-4E50-9CA7-A8D6B17B7886Q40961029-A8D0CAB7-331E-4444-A563-C6BF32DF4397Q42615350-E6E72225-C2D9-41F3-9986-63FB49287B27Q42909398-1F0288E5-7AAA-433F-AD08-A48A7AE0C99EQ43038366-79A6F46E-E116-43C4-8585-77A4BA866EF7Q43040672-FADEB801-9431-4ADF-B6BC-3AC51DBA15B5Q43046510-83965C00-E715-4C1C-A451-3CF821043AA8
P2860
Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Interferon alfa-2b in combinat ...... safety, and pharmacokinetics.
@en
Interferon alfa-2b in combinat ...... safety, and pharmacokinetics.
@nl
type
label
Interferon alfa-2b in combinat ...... safety, and pharmacokinetics.
@en
Interferon alfa-2b in combinat ...... safety, and pharmacokinetics.
@nl
prefLabel
Interferon alfa-2b in combinat ...... safety, and pharmacokinetics.
@en
Interferon alfa-2b in combinat ...... safety, and pharmacokinetics.
@nl
P2093
P356
P1433
P1476
Interferon alfa-2b in combinat ...... safety, and pharmacokinetics.
@en
P2093
Andrew Baczkowski
Barbara Haber
Deirdre A Kelly
Giorgina Mieli-Vergani
International Pediatric Hepatitis C Therapy Group
Karen F Murray
Mark Laughlin
Mark Shelton
Maureen M Jonas
Michael Geffner
P304
P356
10.1002/HEP.20884
P407
P577
2005-11-01T00:00:00Z